Author

Axel Dignass 1

1 Agaplesion Markus Hospital, Dept. of Medicine I, Frankfurt, Germany

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Fernando Gomollon Garcia, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James Lindsay, Laurent Peyrin-Biroulet, Garret Cullen, Marco Daperno, Torsten Kucharzik, Florian Rieder, Sven Almer, Alessandro Armuzzi, Marcus Harbord, Jost Langhorst, Miquel Sans, Yehuda Chowers, Gionata Fiorino, Pascal Juillerat, Geras

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

Paolo Gionchetti, Axel Dignass, Sllvio Danese, Fernando Jose Magro Dias, Gerhard Rogler, Peter L Lakatos, Michel Adamina, Alessandro Ardizzone, Christianne Johanna Buskens, Shaji Sebastian, Silvio Laureti, Gianluca M Sampietro, Boris Vucelic, C. Janneke van der Woude, Manuel Barreiro de Acosta, Christian Maaser, Francisco P

ANALYTICAL PERFORMANCE OF A NEW IPHONE-BASED PATIENT MONITORING SYSTEM COMPARABLE TO ELISA FOR MEASURING FECAL CALPROTECTIN IN IBD PATIENTS

Karl Florian Wintgens, Andina Ayu Wulandari, Axel Dignass, Franz Hartmann, Jürgen Stein

BODY COMPOSITION IN CROHN`S DISEASE PATIENTS BUT NOT IN ULCERATIVE COLITIS PATIENTS IS DIFFERENT COMPARED TO HEALTHY CONTROLS

Chritstoph Dölger, Hermann Schulze, Juliane Thieringer, Jürgen Stein, Axel Dignass

CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE

Alessandro Armuzzi, Nadir Mammar, Benjamin Hoskin, Fritha Hennessy, Puza P. Sharma, Gary Milligan, Ailsa L Hart, Joseph C. Cappelleri, Axel Dignass, John C. Woolcott

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Marc Ferrante, Laurent Peyrin-Biroulet, Axel Dignass, David T. Rubin, Silvio Danese, Geert R. D'Haens, Kristina Kligys, Sofie Berg, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Toshimitsu Fujii, Remo Panaccione

CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Silvio Danese, Severine Vermeire, Geert R. D'Haens, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Fréderic Lavie, Ivana Bravata, Sheldon Sloan, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Lowenberg, Daniel R. Gaya, Laurent Peyrin-Biroulet

Clinical case: An IBD patient with arthralgia & How do guidelines help us?

Axel Dignass, Martine De Vos

Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

Frank Ruemmele, Gabor Laszlo Veres, Kaija-Leena Kolho, Anne Griffiths, Arie Levine, Johanna Caroline Escher, Jorge Amil Dias, Arrigo Barabino, Christian Braegger, Jiri Bronsky, Stephan Buderus, Javier Martín de Carpi, Lissy de Ridder, Ulrika Lorentzon Fagerberg, Jean-Pierre Hugot, J. Kierkus, Sanja Kolacek, Sibylle Koletzk

DEVELOPMENT AND VALIDATION OF A TANDEM LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC (LC-MS/MS) ASSAY FOR THE MEASUREMENT OF VEDOLIZUMAB (VLZ) LEVELS IN PATIENT SERUM

Christina Christ, Axel Dignass, Franz Hartmann, Jürgen Stein, Corinna Berger

Item 1 - 10 / 73
1
2 3 4 5 6 7 8